Mittleman Brothers Lifted Kb Financial Group (KB) Stake; Last Week Quest Diagnostics (DGX) Analysts

January 16, 2018 - By Linda Rogers

Mittleman Brothers Llc increased Kb Financial Group Inc (KB) stake by 6.69% reported in 2017Q3 SEC filing. Mittleman Brothers Llc acquired 28,496 shares as Kb Financial Group Inc (KB)’s stock rose 13.78%. The Mittleman Brothers Llc holds 454,222 shares with $22.27M value, up from 425,726 last quarter. Kb Financial Group Inc now has $23.70 billion valuation. The stock decreased 2.42% or $1.54 during the last trading session, reaching $62.18. About 122,137 shares traded or 10.11% up from the average. KB Financial Group Inc. (NYSE:KB) has risen 65.33% since January 16, 2017 and is uptrending. It has outperformed by 48.63% the S&P500.

Among 21 analysts covering Quest Diagnostics (NYSE:DGX), 7 have Buy rating, 2 Sell and 12 Hold. Therefore 33% are positive. Quest Diagnostics had 57 analyst reports since August 4, 2015 according to SRatingsIntel. Canaccord Genuity maintained Quest Diagnostics Incorporated (NYSE:DGX) on Monday, September 11 with “Buy” rating. As per Tuesday, June 27, the company rating was maintained by Jefferies. Morgan Stanley maintained Quest Diagnostics Incorporated (NYSE:DGX) on Thursday, August 10 with “Underweight” rating. Robert W. Baird maintained the stock with “Hold” rating in Sunday, November 12 report. The rating was upgraded by Mizuho on Tuesday, January 3 to “Buy”. The firm earned “Neutral” rating on Thursday, March 16 by Bank of America. As per Tuesday, September 12, the company rating was maintained by Jefferies. Citigroup maintained the stock with “Neutral” rating in Friday, October 20 report. The company was maintained on Thursday, October 19 by Piper Jaffray. Mizuho maintained the shares of DGX in report on Thursday, October 19 with “Buy” rating. See Quest Diagnostics Incorporated (NYSE:DGX) latest ratings:

05/01/2018 Broker: Evercore Rating: In-Line New Target: $103 Initiates Coverage On
24/11/2017 Broker: Jefferies Rating: Hold New Target: $98.0 Maintain
22/11/2017 Broker: Canaccord Genuity Rating: Buy New Target: $100.0 Maintain
12/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $90.0 Maintain
26/10/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $100 New Target: $105 Maintain
19/10/2017 Broker: Jefferies Rating: Hold New Target: $100.0 Maintain
20/10/2017 Broker: Wells Fargo Rating: Market Perform Old Target: $88 New Target: $86 Maintain
20/10/2017 Broker: Citigroup Rating: Neutral Old Target: $110 New Target: $98 Maintain
19/10/2017 Broker: Mizuho Rating: Buy New Target: $103.0 Maintain
19/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $103.0 Maintain

Among 3 analysts covering HB Financial Group (NYSE:KB), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. HB Financial Group had 3 analyst reports since July 24, 2015 according to SRatingsIntel. Nomura upgraded the stock to “Buy” rating in Friday, July 24 report. The firm has “Overweight” rating given on Monday, February 13 by JP Morgan. The rating was upgraded by Morgan Stanley on Thursday, February 23 to “Overweight”.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $13.82 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 21.26 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

Investors sentiment decreased to 0.98 in 2017 Q3. Its down 0.01, from 0.99 in 2017Q2. It worsened, as 51 investors sold Quest Diagnostics Incorporated shares while 184 reduced holdings. 57 funds opened positions while 173 raised stakes. 116.90 million shares or 2.64% more from 113.89 million shares in 2017Q2 were reported. Seaward Lp holds 8,680 shares or 0.04% of its portfolio. Stellar Cap Management Limited Liability Co owns 28,513 shares or 1.88% of their US portfolio. Sun Life has 1,004 shares for 0.01% of their portfolio. Commercial Bank Of Mellon Corporation accumulated 1.16M shares. Fifth Third Bancshares invested in 0% or 197 shares. Bnp Paribas Asset owns 0.1% invested in Quest Diagnostics Incorporated (NYSE:DGX) for 126,329 shares. 3,618 are owned by Kentucky Retirement Ins Fund. Sumitomo Mitsui Tru holds 0.06% in Quest Diagnostics Incorporated (NYSE:DGX) or 432,302 shares. Paloma Mgmt Company holds 29,589 shares or 0.04% of its portfolio. Gam Ag stated it has 0.11% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Citadel Limited Liability Corp reported 317,199 shares stake. Ny State Teachers Retirement has 0.05% invested in Quest Diagnostics Incorporated (NYSE:DGX) for 234,316 shares. Moreover, First Allied Advisory has 0.01% invested in Quest Diagnostics Incorporated (NYSE:DGX). Pggm Invs reported 0.16% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Baker Ellis Asset Limited Liability accumulated 0.06% or 2,250 shares.

Since August 4, 2017, it had 0 buys, and 6 sales for $17.85 million activity. STANZIONE DANIEL sold $410,762 worth of stock. RUSCKOWSKI STEPHEN H had sold 2,525 shares worth $272,768. On Tuesday, January 2 the insider Davis J. E. sold $6.30 million. $31,571 worth of Quest Diagnostics Incorporated (NYSE:DGX) shares were sold by LEIDEN JEFFREY M.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts